Mersana Therapeutics, Inc.
MRSN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.92 | -0.01 | -0.14 |
| FCF Yield | -8.25% | -61.25% | -68.49% | -10.90% |
| EV / EBITDA | 2.18 | 0.83 | 1.51 | -7.61 |
| Quality | ||||
| ROIC | -34.44% | -44.87% | -34.64% | -15.03% |
| Gross Margin | 100.00% | 90.61% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.42 | 0.93 | 1.22 | 1.36 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.69% | -3.52% | 1.68% | 15.07% |
| Free Cash Flow Growth | 85.88% | 22.93% | -52.33% | -124.45% |
| Safety | ||||
| Net Debt / EBITDA | 7.65 | 2.41 | 3.37 | 6.18 |
| Interest Coverage | -18.97 | -30.53 | -31.63 | -16.40 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 1.37 | -908.79 | 0.00 | 0.00 |